AKBA - Akebia Therapeutics, Inc.
After hours:
Chart Events
Price Crosses Moving Average
Performance Outlook
- Short Term2W - 6W
- Mid Term6W - 9M
- Long Term9M+
| Previous Close | 1.2000 |
| Open | 1.2200 |
| Bid | 1.2700 x 3200 |
| Ask | 1.2700 x 1800 |
| Day's Range | 1.2100 - 1.3200 |
| 52 Week Range | 0.2410 - 1.6300 |
| Volume | |
| Avg. Volume | 1,724,971 |
| Market Cap | 237.988M |
| Beta (5Y Monthly) | 0.73 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3300 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
Fair Value
Related Research
ZacksAll You Need to Know About Akebia Therapeutics (AKBA) Rating Upgrade to Buy
Akebia Therapeutics (AKBA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ZacksAre Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year?
Here is how Akebia Therapeutics (AKBA) and Brookdale Senior Living (BKD) have performed compared to their sector so far this year.
PR NewswireAkebia Therapeutics to Present at Jefferies Healthcare Conference
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will present at the Jefferies Healthcare Conference on Wednesday, June 7, 2023 at 8:30 a.m. ET. In his presentation, Mr. Butler will discuss recent regulatory updates regarding vadadustat, Akebia's oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia due to chro
- PR Newswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 29,000 shares of Akebia's common stock on May 31, 2023, as inducements material to such employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
- PR Newswire
FDA Provides Akebia Therapeutics a Path Forward for Vadadustat
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company received a written response from the Office of New Drugs (OND) of the U.S. Food and Drug Administration (FDA) to Akebia's Formal Dispute Resolution Request (FDRR) regarding the Complete Response Letter (CRL) received in March 2022 for vadadustat. The letter from the OND stated the company's appeal was denied; however, t
- PR Newswire
Akebia Therapeutics Enters into License Agreement with Medice Arzneimittel Pütter GmbH&Co.KG for the Commercialization of Vafseo® for the Treatment of Anemia associated with CKD in Europe and Australia
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced an agreement with MEDICE Arzneimittel Pütter GmbH&Co.KG (Medice – The Health Family), for Medice to market Vafseo® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor developed by Akebia to treat anemia due to chronic kidney disease (CKD), in Europe. Akebia is retaining the rights to develop and commerci
Motley FoolWhy Shares of Akebia Therapeutics Were Up Tuesday
Shares of Akebia Therapeutics (NASDAQ: AKBA) were up more than 10% Tuesday after rising to as high as 13.1% in early trading. The biopharmaceutical company, which specializes in therapies to fight kidney disease, has seen its shares climb more than 168% so far this year. On Monday, the company announced that the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) had granted marketing approval for Vafseo (vadadustat) to treat anemia connected with chronic kidney disease in adults on maintenance dialysis.
- PR Newswire
Akebia Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has received a formal notice from The Nasdaq Stock Market (Nasdaq) stating that Akebia has regained compliance with the $1.00 per share minimum bid price requirement pursuant to Nasdaq Listing Rule 5550(a)(2), and that Akebia is in compliance with all applicable listing standards.
- PR Newswire
Akebia Announces UK MHRA Approval of Vafseo® (vadadustat) for the Treatment of Symptomatic Anemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis
Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for Vafseo® (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.
ZacksIs Novartis (NVS) Stock Outpacing Its Medical Peers This Year?
Here is how Novartis (NVS) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
- Thomson Reuters StreetEvents
Q1 2023 Akebia Therapeutics Inc Earnings Call
Q1 2023 Akebia Therapeutics Inc Earnings Call
ZacksAkebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates
Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 6.67% and 14.05%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Akebia Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today reported financial results for the first quarter ended March 31, 2023 and provided business highlights.
ZacksWill CTI BioPharma (CTIC) Report Negative Earnings Next Week? What You Should Know
CTI BioPharma (CTIC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Will Akebia Therapeutics (AKBA) Report Negative Q1 Earnings? What You Should Know
Akebia Therapeutics (AKBA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- PR Newswire
Akebia Therapeutics to Report First Quarter Financial Results and Discuss Recent Business Highlights
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the first quarter ended March 31, 2023 on Monday, May 8, 2023, prior to the open of financial markets.
- PR Newswire
Akebia Receives European Commission Approval for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis
Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced that the European Commission (EC) has granted marketing authorisation for Vafseo™ (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis. The approval is applicable to all 27 European Union member states plus Iceland, Norway and Liechtenstein. Vadadustat is now approved in 32 countri
Simply Wall St.Benign Growth For Akebia Therapeutics, Inc. (NASDAQ:AKBA) Underpins Its Share Price
With a price-to-sales (or "P/S") ratio of 0.4x Akebia Therapeutics, Inc. ( NASDAQ:AKBA ) may be sending very bullish...
- PR Newswire
Akebia Therapeutics to Host Stockholder Information Session to Discuss Rationale for Reverse Stock Split
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will host a stockholder information session on Friday, April 21 at 8:00 a.m. ET to discuss its upcoming special meeting of stockholders (Special Meeting) to seek stockholder approval to, among other things, effect a reverse stock split of Akebia's outstanding common stock, which Akebia believes would allow it to regain compliance
- PR Newswire
Akebia Therapeutics Announces Adjournment of Special Meeting of Stockholders
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it adjourned, without conducting any business, the special meeting of stockholders (the "Special Meeting") on Tuesday, April 11, 2023 to allow the company to solicit from its stockholders the additional proxies necessary to obtain approval of the proposals described in the company's revised definitive proxy statement filed with the
- PR Newswire
Akebia Therapeutics Announces Poster Presentations at National Kidney Foundation Spring Clinical Meetings 2023
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present posters at the National Kidney Foundation (NKF) Spring Clinical Meetings 2023 (SCM23), which will take place on demand and live in Austin, Texas on April 11 – 15, 2023.
- PR Newswire
Akebia Therapeutics Announces Positive Top-Line Results from Vadadustat Alternative Dosing Study
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced positive top-line results from FO2CUS, a study evaluating the efficacy and safety of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, in hemodialysis patients who were converted from a long-acting erythropoiesis-stimulating agent (ESA) to three times weekly oral vadadustat dosing for the maintenance tr
- PR Newswire
Akebia Therapeutics Provides Update on Regulatory Process for Vadadustat
Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the company met with the U.S. Food and Drug Administration (FDA) Office of New Drugs (OND) deciding authority to discuss Akebia's Formal Dispute Resolution regarding the Complete Response Letter for vadadustat received in March 2022.
- PR Newswire
Akebia Therapeutics Files Revised Definitive Proxy Statement for Special Stockholder Meeting
Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that it has filed a revised definitive proxy statement with the Securities and Exchange Commission (SEC) in connection with a special meeting (Special Meeting) of stockholders scheduled on April 11, 2023 at 10:00 a.m. ET in a virtual meeting format as a live webcast. Akebia is holding the Special Meeting to seek stockholder approval to, among
Insider MonkeyAkebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2022 Earnings Call Transcript
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q4 2022 Earnings Call Transcript March 9, 2023 Operator: Good day ladies and gentlemen. Thank you for standing by and welcome to Akebia’s Fourth Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. Please […]
